Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

EPICAR 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/EPICAR 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

Approved

STANDARD

EPICAR 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

Laboratorios Alter S.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: May 26, 2022
Approval ID: 18c37dfd59e6a686
Company: Laboratorios Alter S.A.
Type: Standard

Approval Details

Approval Id: 18c37dfd59e6a686
Drug Cima Aemps Name: EPICAR 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG
Register Number: 87459
Holder Company Name: Laboratorios Alter S.A.
Marketing Company Name: Laboratorios Alter S.A.
Authorization Date: 2022-05-26
Dosage Form: COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose: 10 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Laboratorios Alter S.A.

Active Ingredients

RIVAROXABAN

10 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

May 26, 2022

Approval ID

18c37dfd59e6a686

Type

Standard

Back to CIMA-AEMPS Approvals